Biggest News Aggregation in the World
📰 Alpn News

Page 6 - Alpn News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Alpn. Real-time updates on events, politics, business and more.

Alpine Immune Sciences, Inc. to Post Q1 2024 Earnings of ($0.41) Per Share, Oppenheimer Forecasts (NASDAQ:ALPN)

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Oppenheimer issued their Q1 2024 earnings per share estimates for shares of Alpine Immune Sciences in a research note issued to investors on Friday, March 24th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($0.41) per share for the quarter. The […]
United States Charles Schwab Investment Management Inc Morgan Stanley Alpine Immune Sciences Inc Alpine Immune Sciences Jpmorgan Chase Co

Alpine Immune Sciences (NASDAQ:ALPN) Price Target Raised to $11.00

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) had its price objective increased by HC Wainwright from $8.00 to $11.00 in a research report report published on Friday morning, The Fly reports. HC Wainwright also issued estimates for Alpine Immune Sciences’ Q2 2023 earnings at ($0.35) EPS and Q3 2023 earnings at ($0.39) EPS. Separately, Morgan […]
United States Alpine Immune Sciences Inc Lazard Asset Management Alpine Immune Sciences Trading Down Morgan Stanley Alpine Immune Sciences

Alpine Immune Sciences (NASDAQ:ALPN) Stock Price Crosses Above Two Hundred Day Moving Average of $8.46

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $8.46 and traded as high as $8.94. Alpine Immune Sciences shares last traded at $8.80, with a volume of 60,111 shares changing hands. Analyst Upgrades and […]
Alpine Immune Sciences Company Profile Crossover Management Alpine Immune Sciences Alpine Immune Sciences Inc Frazier Management Alpine Immune Sciences Price Performance

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Alpine Immune Sciences Inc.: Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

- ALPN-303 uniquely binds BAFF and APRIL with high affinity, differentiating from related inhibitors including wild-type TACI-Fc's - - Ongoing phase 1 study demonstrates highly encouraging preliminary
Stanford Peng Alex Sharif Kelli Perkins European Congress Head Of Research Alpine Immune Sciences

Alpine Immune Sciences (NASDAQ:ALPN) Issues Quarterly Earnings Results

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative net margin of 214.70% and a negative return on equity of 59.07%. […]
United States Geode Capital Management Alpine Immune Sciences Zacks Investment Research Earnings History For Alpine Immune Sciences Alpine Immune Sciences Inc

Alpine Immune Sciences (NASDAQ:ALPN) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%. NASDAQ […]
Goldman Sachs Group Inc Alpine Immune Sciences Zacks Investment Research Blackrock Inc Earnings History For Alpine Immune Sciences Alpine Immune Sciences Inc

Alpine Immune Sciences (NASDAQ:ALPN) Issues Earnings Results, Misses Estimates By $0.06 EPS

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%. NASDAQ:ALPN […]
Goldman Sachs Group Inc Alpine Immune Sciences Zacks Investment Research Earnings History For Alpine Immune Sciences Alpine Immune Sciences Inc Alpine Immune Sciences Company Profile Get Rating

Zacks: Analysts Anticipate Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Will Post Quarterly Sales of $13.35 Million

Wall Street analysts expect that Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) will post sales of $13.35 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Alpine Immune Sciences’ earnings, with estimates ranging from $5.93 million to $20.00 million. Alpine Immune Sciences posted sales of $3.20 million in […]
United States Allspring Global Investments Holdings Alpine Immune Sciences Zacks Investment Research Alpine Immune Sciences Inc America Corp

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science